Amoxicillin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AMOXIL | — | 1998-02-27 | fda.gov ↗ |
| Approved | US (FDA) | AMOXIL | — | 1974-01-18 | fda.gov ↗ |
Trials 436 · started per year
Also used as a comparator or background therapy in 402 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06901375 Background | May → Aug 2025 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT06197308 Background | Mar 2024 → Mar 2027 expected | primary sclerosing cholangitis | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT05726253 Comparator | Jan → Dec 2023 | pneumonia | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT05100654 Comparator | Apr 2022 → Dec 2027 expected | erectile dysfunction, prosthesis-related infectious disease | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04963764 Comparator | Oct 2021 → May 2022 | pneumonia | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT05100446 Comparator | May → Dec 2021 | Helicobacter pylori infectious disease, gastric cancer, gastritis | Unidade Local de Saúde do Alto Ave, EPE | Unknown | No outcome recorded |
| Phase 0 | NCT04414722 Background | Jan 2021 → May 2023 | diarrheal disease | Georgetown University | Completed | No outcome recorded |
| Phase 0 | NCT03755765 Background | Jul 2019 → Jan 2020 | diarrheal disease | Georgetown University | Completed | No outcome recorded |
| Phase 0 | NCT02837614 Background | Oct 2015 → Jan 2016 | impacted teeth, multiple | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07294846 Background | Sep → Dec 2025 | — | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06733675 Comparator | Jan 2025 → Dec 2026 expected | — | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase 1 | NCT05586464 Comparator | Nov 2022 → Sep 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04376554 Comparator | Feb 2020 → Apr 2021 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02998437 Comparator | Dec 2016 → Jan 2017 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02892409 Background | Sep 2016 → Apr 2017 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02431832 Background | Feb → Oct 2015 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01851681 Comparator | Jul 2014 → May 2017 | — | University of Montreal | Completed | No outcome recorded |
| Phase 1 | NCT01967758 Background | Jan 2014 → Jun 2018 | anaplastic astrocytoma, brain neoplasm, glioblastoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01635608 Comparator | Apr → Jul 2011 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01229046 Comparator | Sep 2010 → ? | infectious disease with sepsis | Phillip Brian Smith | Withdrawn | No outcome recorded |
| Phase 1 | NCT00873327 Comparator | Oct 2009 → Jul 2010 | infectious disease with sepsis | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 1 | NCT03654781 Background | Apr 2008 → Jul 2011 | Helicobacter pylori infectious disease | Ondokuz Mayıs University | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07096310 Comparator | Jan 2024 → Jan 2026 overdue | infectious disease with sepsis | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05461508 Background | Oct 2022 → Jun 2024 | Helicobacter pylori infectious disease, post-bacterial disorder | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT06823791 Background | Aug 2022 → Jul 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03727620 Comparator | Jan → Jun 2014 | periodontitis, aggressive | Mohammed V Souissi University | Completed | No outcome recorded |
| Phase 1/2 | NCT02803216 Background | Jan 2013 → Dec 2015 | Helicobacter pylori infectious disease | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT03130933 Comparator | Apr 2010 → Nov 2016 | impacted teeth, multiple | University of Zagreb | Completed | No outcome recorded |
| Phase 1/2 | NCT00817245 Comparator | Mar → Oct 2008 | central serous chorioretinopathy | Tabriz University | Completed | No outcome recorded |
| Phase 227 trials | ||||||
| Phase 2 | NCT07492134 Comparator | Jul 2026 → Apr 2028 expected | diverticulitis | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07318584 Comparator | Mar 2026 → Feb 2028 expected | escherichia coli discitis | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07202949 Comparator | Feb 2026 → Oct 2027 expected | urinary tract infection | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT07293910 Comparator | Feb → Dec 2026 expected | Helicobacter pylori infectious disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06973889 Background | Dec 2023 → Dec 2024 | Helicobacter pylori infectious disease, digestive system disorder | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05266040 Background | Oct 2023 → Dec 2025 overdue | acute apical periodontitis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT05957432 Comparator | Aug 2023 → Oct 2025 overdue | Helicobacter pylori infectious disease | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05933031 Comparator | Feb 2023 → Dec 2024 | Helicobacter pylori infectious disease | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT04983901 Comparator | Sep 2021 → Oct 2023 | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03986996 Comparator | Jul 2019 → May 2022 | ulcerative colitis | Wolfson Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03818815 Comparator | Feb 2019 → Mar 2020 | otitis media | Novus Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT03761264 Comparator | Sep 2018 → Feb 2020 | dental abscess | University of Malaya | Completed | No outcome recorded |
| Phase 2 | NCT03968302 Background | Jun 2018 → May 2019 | Helicobacter pylori infectious disease | Ziauddin University | Completed | No outcome recorded |
| Phase 2 | NCT03315676 Comparator | Nov 2017 → Nov 2022 | ulcer disease | Shinshu University | Unknown | No outcome recorded |
| Phase 2 | NCT03078010 Comparator | Feb 2017 → Feb 2027 expected | neutropenia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02761005 Background | May 2016 → Mar 2018 | Helicobacter pylori infectious disease | Hamamatsu University | Unknown | No outcome recorded |
| Phase 2 | NCT02517099 Comparator | Jun 2015 → Aug 2018 | asthma | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT02090738 Comparator | Mar → Dec 2014 | Helicobacter pylori infectious disease | Yonsei University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01963442 Comparator | Nov 2013 → Jun 2018 | — | Versailles Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01946256 Comparator | Oct 2013 → Mar 2014 | chlamydia trachomatis infectious disease | Obafemi Awolowo University Teaching Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01805934 Comparator | May → Dec 2012 | — | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01511107 Comparator | Jan 2012 → Sep 2015 | otitis media | Alejandro Hoberman | Terminated | No outcome recorded |
| Phase 2 | NCT01513785 Comparator | Apr → Oct 2011 | dyspepsia | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01002443 Comparator | Jul 2003 → Mar 2006 | gastric cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00066066 Comparator | Jul 2003 → Jul 2009 | periodontitis | The Forsyth Institute | Completed | No outcome recorded |
| Phase 2 | NCT00750750 Comparator | Jan → Sep 2003 | sinusitis | Organon and Co | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT06591494 Comparator | Sep 2024 → Sep 2025 overdue | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05861687 Background | Aug → Dec 2021 | Helicobacter pylori infectious disease | Finni Kollins | Completed | No outcome recorded |
| Phase 2/3 | NCT04879030 Background | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT02753946 Comparator | Apr 2016 → Jan 2017 | acute pyelonephritis | Nabriva Therapeutics AG | Completed | No outcome recorded |
| Phase 2/3 | NCT02605122 Comparator | Apr 2016 → Mar 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT03132714 Comparator | Mar 2015 → Oct 2016 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT02969928 Comparator | Mar 2015 → Dec 2016 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT01994993 Comparator | Dec 2013 → Jan 2017 | — | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 2/3 | NCT01530763 Background | Sep 2012 → Apr 2014 | infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 2/3 | NCT00716183 Comparator | Jul 2008 | mastitis | Universidad Complutense de Madrid | Completed | No outcome recorded |
| Phase 371 trials | ||||||
| Phase 3 | NCT06123169 Comparator | Jul 2026 → Sep 2028 expected | — | University Hospital, Rouen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07606833 Background | Jun 2026 → Feb 2027 expected | Helicobacter pylori infectious disease | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07576959 Background | Apr 2026 → Dec 2030 expected | Helicobacter pylori infectious disease | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07275827 Comparator | Feb → Apr 2026 overdue | Helicobacter pylori infectious disease | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07582549 Comparator | Dec 2025 → Dec 2027 expected | — | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06964334 Comparator | Jun 2025 → Jun 2026 overdue | Helicobacter pylori infectious disease | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06811207 Background | Feb 2025 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT06055257 Background | Jan 2025 → Dec 2027 expected | osteoradionecrosis of the mandible | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT06443502 Background | Nov 2024 → Dec 2029 expected | pouchitis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06734260 Comparator | Sep 2024 → Nov 2025 overdue | — | Eighth Affiliated Hospital, Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05681312 Comparator | May → Sep 2024 | — | University of Baghdad | Unknown | No outcome recorded |
| Phase 3 | NCT05902221 Comparator | May 2024 → May 2028 expected | periprosthetic joint infection | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT06340724 Background | Feb → Nov 2024 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| Phase 3 | NCT06751121 Background | Feb 2024 → Apr 2025 | Helicobacter pylori infectious disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT06162949 Background | Jan → Aug 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT07304882 Background | Nov 2023 → Jan 2025 | impacted teeth, multiple | University of Science and Technology, Yemen | Completed | No outcome recorded |
| Phase 3 | NCT06414707 Comparator | Oct 2023 → Apr 2024 | Helicobacter pylori infectious disease | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05857163 Background | May → Dec 2023 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05473234 Comparator | Oct 2022 → Nov 2023 | protein-energy malnutrition | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 3 | NCT05728424 Comparator | Sep 2022 → Apr 2023 | Helicobacter pylori infectious disease | Aga Khan University | Unknown | No outcome recorded |
| Phase 3 | NCT04698057 Background | Mar 2022 → Jun 2025 | neutropenia | Poitiers University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT05392634 Comparator | Feb 2022 → Feb 2023 | urinary bladder cancer | N.N. Petrov National Medical Research Center of Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT06101420 Background | Jan 2022 → Jun 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04549311 Comparator | Nov 2021 → Jan 2023 | anal fistula | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT04652284 Comparator | May 2021 → May 2023 | Helicobacter pylori infectious disease, bacterial gastritis, primary bacterial infectious disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03568643 Comparator | Jun → Dec 2020 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT05863858 Comparator | Jun 2020 → Dec 2021 | Helicobacter pylori infectious disease | Iyad Naeem Muhammad, PhD | Completed | No outcome recorded |
| Phase 3 | NCT04198363 Background | Apr 2020 → Nov 2021 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT04128917 Background | Jan → Dec 2020 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03966014 Comparator | Jun 2019 → Dec 2027 expected | — | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 3 | NCT03582007 Comparator | Oct 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03358576 Comparator | Sep 2018 → Oct 2019 | intestinal infectious disease | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03357614 Comparator | Sep 2018 → Dec 2019 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT04209777 Comparator | Jul 2018 → Apr 2019 | chronic periodontitis | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03498456 Comparator | Jun 2018 → Dec 2019 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03409679 Comparator | Mar 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03317223 Background | Oct 2017 → Jan 2019 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03198507 Background | Jun 2017 → Oct 2018 | Helicobacter pylori infectious disease, dyspepsia | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT03050307 Background | Apr 2017 → Feb 2020 | gastric ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03050359 Background | Apr 2017 → Mar 2019 | duodenal ulcer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03060473 Background | Feb 2017 → Dec 2023 | preterm premature rupture of the membranes | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 3 | NCT02820987 Comparator | Sep 2016 → Oct 2018 | infectious disease with sepsis | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 3 | NCT02473263 Comparator | May 2016 → Feb 2019 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02554383 Comparator | Feb 2016 → Mar 2022 | respiratory tract infectious disorder, sinusitis | Nader Shaikh | Completed | No outcome recorded |
| Phase 3 | NCT02281929 Comparator | Jun 2015 → Nov 2019 | alcoholic hepatitis | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT03142620 Comparator | Mar 2015 → Dec 2017 | Helicobacter pylori infectious disease | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT02368470 Background | Feb → Aug 2015 | Helicobacter pylori infectious disease | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03362281 Background | Oct 2014 → Apr 2015 | active peptic ulcer disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03374176 Comparator | Mar 2014 → Jul 2016 | chronic periodontitis, type 2 diabetes mellitus | Centro Universitario de Tonalá | Completed | No outcome recorded |
| Phase 3 | NCT02021006 Comparator | Dec 2013 → Jan 2020 | chronic kidney disease, renal hypodysplasia/aplasia 1, vesicoureteral reflux | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 3 | NCT03208361 Comparator | Nov 2013 → Mar 2016 | pneumonia | Jordi Gol Institute for Primary Care Research | Terminated | No outcome recorded |
| Phase 3 | NCT02974348 Background | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT02726269 Comparator | Jun 2012 → Mar 2014 | Helicobacter pylori infectious disease | Asofarma de México S.A de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT01505127 Background | Jan 2012 → Jun 2013 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01370616 Background | Sep 2011 → Dec 2013 | skin infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01069900 Comparator | Jul 2010 → Jan 2015 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01015417 Comparator | May 2010 → Nov 2012 | acute cholecystitis | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT01733966 Comparator | May 2010 → Mar 2012 | diverticulitis of colon | Quanta Medical | Terminated | No outcome recorded |
| Phase 3 | NCT00828971 Comparator | Nov 2008 → Sep 2009 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00669955 Comparator | Jun 2008 → Jul 2009 | Helicobacter pylori infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00933049 Comparator | Jul 2007 → Jan 2008 | pneumonia | Makerere University | Completed | No outcome recorded |
| Phase 3 | NCT00445497 Background | Jul 2007 → Jul 2010 | central nervous system neoplasm, lymphoma, neutropenia, small intestine cancer | Clatterbridge Centre for Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT00393744 Comparator | Oct 2006 → Mar 2008 | tonsillitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00402727 Comparator | Sep 2006 → Jun 2008 | abscess, skin infection, ulcer disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01510730 Comparator | Jan 2005 → Feb 2011 | Helicobacter pylori infectious disease, gastric neoplasm | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00934830 Comparator | Jan 2005 → Oct 2008 | sinusitis | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT01678027 Comparator | Nov 2004 → Dec 2018 overdue | Helicobacter pylori infectious disease, gastric cancer | National Cancer Center, Korea | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00751075 Comparator | Dec 2003 → May 2004 | sinusitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT02407119 Comparator | Jun 2003 → Jun 2016 overdue | Helicobacter pylori infectious disease, gastric carcinoma | National Cancer Center, Korea | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00644553 Comparator | May 2003 → Mar 2004 | sinusitis | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00649831 Comparator | Oct 2002 → Jun 2003 | chronic bronchitis | Pfizer | Completed | No outcome recorded |
| Phase 4167 trials | ||||||
| Phase 4 | NCT07625267 Comparator | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07275580 Comparator | Jun 2026 → Jun 2029 expected | rheumatic disorder | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06712641 Comparator | Apr 2026 → Jun 2028 expected | infectious disease with sepsis | University Hospital, Akershus | Recruiting | No outcome recorded |
| Phase 4 | NCT07537634 Background | Apr → Aug 2026 overdue | Helicobacter pylori infectious disease, dyspepsia, peptic ulcer disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Show all 167 trials opens the full record — a long page | ||||||
| Phase not applicable97 trials | ||||||
| — | NCT07533422 Comparator | May → Dec 2026 expected | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07352098 Background | Feb 2026 → Feb 2028 expected | Helicobacter pylori infectious disease | Yueyue Li | Not yet recruiting | No outcome recorded |
| — | NCT07296302 Comparator | Feb → Oct 2026 expected | — | Agnaldo Rocha de Souza Junior | Not yet recruiting | No outcome recorded |
| — | NCT07358130 Comparator | Oct 2025 → Nov 2027 expected | Helicobacter pylori infectious disease | Kaohsiung Medical University | Recruiting | No outcome recorded |
| — | NCT06869850 Background | Sep 2025 → Dec 2027 expected | cognitive impairment with or without cerebellar ataxia, kwashiorkor | Washington University School of Medicine | Recruiting | No outcome recorded |
| — | NCT07179159 Background | Sep 2025 → Aug 2026 overdue | Helicobacter pylori infectious disease | Yanqing Li | Recruiting | No outcome recorded |
| — | NCT06906757 Comparator | Sep 2025 → Dec 2029 expected | preterm premature rupture of the membranes | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT07159412 Background | Aug 2025 → Aug 2026 overdue | Helicobacter pylori infectious disease, metabolic dysfunction-associated steatohepatitis | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06851468 Background | Mar → Nov 2025 | Helicobacter pylori infectious disease | Key Laboratory for Gastrointestinal Diseases of Gansu Province | Completed | No outcome recorded |
| — | NCT06850714 Background | Feb → Jun 2025 overdue | poisoning | Liaquat University of Medical & Health Sciences | Not yet recruiting | No outcome recorded |
| — | NCT06299605 Comparator | Nov 2024 → Oct 2025 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT07148622 Comparator | Oct 2024 → Aug 2025 | preterm premature rupture of the membranes | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT07260006 Background | Oct 2024 → May 2026 overdue | Helicobacter pylori infectious disease, peptic ulcer disease | Can Tho University of Medicine and Pharmacy | Recruiting | No outcome recorded |
| — | NCT06207786 Background | Sep 2024 → May 2029 | epidermal appendage tumor, skin cancer | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT06412588 Comparator | Jun 2024 → Jan 2026 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| — | NCT07233733 Background | Jun 2024 → Mar 2025 | periodontitis | Phạm Đình Thiên Khải | Completed | No outcome recorded |
| — | NCT06080698 Comparator | Feb 2024 → May 2027 expected | gram-negative bacterial infections | Johns Hopkins University | Recruiting | No outcome recorded |
| — | NCT06250413 Background | Feb 2024 → Dec 2026 expected | poisoning | Otto Helve | Not yet recruiting | No outcome recorded |
| — | NCT06292546 Background | Jan → Dec 2024 | metabolic disease | Zhongshan Hospital (Xiamen), Fudan University | Completed | No outcome recorded |
| — | NCT06154174 Background | Dec 2023 → Nov 2026 expected | cognitive disorder, kwashiorkor | Washington University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06349486 Comparator | Nov 2023 → Dec 2026 expected | — | Kaohsiung Medical University | Recruiting | No outcome recorded |
| — | NCT05840588 Background | Nov 2023 → Mar 2025 | bacterial infectious disease | Liaquat University of Medical & Health Sciences | Completed | No outcome recorded |
| — | NCT06061484 Background | Sep 2023 → Sep 2026 expected | protein-energy malnutrition | Action Against Hunger USA | Recruiting | No outcome recorded |
| — | NCT05870683 Background | May → Oct 2023 | Helicobacter pylori infectious disease | Yanqing Li | Unknown | No outcome recorded |
| — | NCT04856319 Comparator | Sep 2022 → Sep 2023 | tooth disorder | Biruni University | Unknown | No outcome recorded |
| — | NCT05916716 Background | Aug 2022 → Dec 2023 | gingival recession | São Paulo State University | Unknown | No outcome recorded |
| — | NCT05361499 Background | May 2022 → Feb 2023 | pneumococcal infection | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT05916742 Background | Apr 2022 → Dec 2023 | gingival recession | São Paulo State University | Unknown | No outcome recorded |
| — | NCT05189444 Comparator | Mar → Dec 2022 | Helicobacter pylori infectious disease | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT05248620 Comparator | Feb 2022 → Oct 2028 expected | — | Zealand University Hospital | Recruiting | No outcome recorded |
| — | NCT05804123 Background | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT05410223 Background | Apr 2021 → Dec 2022 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT04803422 Comparator | Apr 2021 → May 2024 | appendicitis | Zealand University Hospital | Completed | No outcome recorded |
| — | NCT05035186 Background | Mar → Sep 2021 | Helicobacter pylori infectious disease | Alexandria University | Completed | No outcome recorded |
| — | NCT06382493 Background | Feb 2021 → Dec 2026 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT04751500 Comparator | Jan 2021 → Nov 2022 | — | Birmingham Women's and Children's NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT04721704 Background | Sep 2020 → Sep 2022 | bacterial gastritis | Shaheed Zulfiqar Ali Bhutto Medical University | Unknown | No outcome recorded |
| — | NCT04359966 Comparator | May 2020 → May 2023 | Helicobacter pylori infectious disease | Slovenian Society for Gastroenterology and Hepatology | Unknown | No outcome recorded |
| — | NCT05850117 Comparator | Feb 2020 → Dec 2024 | — | Kaohsiung Medical University | Unknown | No outcome recorded |
| — | NCT04566211 Comparator | Jan 2020 → Sep 2022 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| — | NCT03844776 Comparator | Oct 2019 → Dec 2020 | infectious disease | Taibah University | Unknown | No outcome recorded |
| — | NCT04048304 Background | Jul 2019 → Feb 2025 overdue | infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| — | NCT04438655 Background | May 2019 → Nov 2021 | — | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT04621487 Comparator | Jan 2019 → Jan 2020 | Helicobacter pylori infectious disease | University of Split, School of Medicine | Completed | No outcome recorded |
| — | NCT03688828 Background | Nov 2018 → Jun 2020 | Helicobacter pylori infectious disease | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT03431688 Comparator | Oct 2018 → Oct 2020 | Helicobacter pylori infectious disease | Kangdong Sacred Heart Hospital | Completed | No outcome recorded |
| — | NCT03779087 Comparator | Jul 2018 → Jun 2020 | Helicobacter pylori infectious disease | Ping-I (William) Hsu, M.D. | Completed | No outcome recorded |
| — | NCT03572777 Background | Apr 2018 → Oct 2019 | Helicobacter pylori infectious disease | Antonio Mestrovic | Completed | No outcome recorded |
| — | NCT04215770 Comparator | Jan 2018 → Nov 2019 | streptococcal sore throat | Combined Military Hospital, Pakistan | Completed | No outcome recorded |
| — | NCT03362697 Comparator | Dec 2017 → Dec 2018 | bacterial urinary tract infection | Innovacion y Desarrollo de Estrategias en Salud | Completed | No outcome recorded |
| — | NCT03499184 Comparator | Nov 2017 → Sep 2018 | chronic periodontitis | Ziauddin Hospital | Completed | No outcome recorded |
| — | NCT03094247 Background | Oct 2017 → Mar 2021 | protein-energy malnutrition | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT03295955 Comparator | Sep 2017 → Sep 2018 | nodular goiter | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT03607734 Background | Apr → Oct 2017 | allergic disease | The Leeds Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT03829150 Background | Mar 2017 → Apr 2019 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT04620018 Comparator | Sep 2016 → Feb 2020 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT02867982 Background | Jul 2016 → Dec 2019 | bone resorption disease | Beijing University Health Science Center | Unknown | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT03043066 Comparator | Mar → Jul 2016 | chronic periodontitis | Meenakshi Ammal Dental College and Hospital | Completed | No outcome recorded |
| — | NCT02954393 Comparator | May 2015 → Dec 2019 | chronic periodontitis | Belén Retamal-Valdes | Unknown | No outcome recorded |
| — | NCT02978157 Comparator | Feb 2015 → Sep 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02547038 Comparator | Feb 2015 → Oct 2018 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02315547 Background | Jan 2015 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT02372461 Comparator | Nov 2014 → Nov 2017 | persistent tachypnoe of infancy, usual, pneumonia | Aga Khan University | Completed | No outcome recorded |
| — | NCT02373280 Comparator | Aug 2014 → Apr 2027 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT02054676 Background | Feb 2014 → Apr 2016 | — | Lithuanian University of Health Sciences | Unknown | No outcome recorded |
| — | NCT02053857 Background | Feb → Jul 2014 | kwashiorkor, marasmus | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02198001 Comparator | Jan 2014 → Jan 2016 | osteonecrosis of the jaw | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| — | NCT02115776 Comparator | Jan 2014 → Apr 2015 | bacterial infectious disease | University of Santiago de Compostela | Completed | No outcome recorded |
| — | NCT02108704 Comparator | Dec 2013 → Dec 2015 | Helicobacter pylori infectious disease, Parkinson disease | University of Malaya | Completed | No outcome recorded |
| — | NCT02547012 Background | Nov 2013 → Jul 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02541864 Comparator | Jul 2013 → Aug 2015 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01613547 Comparator | Oct 2012 → Mar 2014 | protein-energy malnutrition | Epicentre | Completed | No outcome recorded |
| — | NCT02359435 Background | Oct 2012 → Feb 2015 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01761214 Comparator | Sep 2012 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT01593592 Background | Jun 2012 → Jan 2013 | Helicobacter pylori infectious disease | Zagazig University | Completed | No outcome recorded |
| — | NCT01715610 Comparator | May 2012 → Nov 2015 | peritonsillar abscess | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| — | NCT01473368 Comparator | Apr 2012 → Feb 2013 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT01507974 Comparator | Jan 2012 → Jul 2014 | pregnancy disorder | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01530009 Comparator | Jan 2012 → Jan 2022 | — | Nationwide Children's Hospital | Completed | No outcome recorded |
| — | NCT01930955 Comparator | Aug 2011 → Dec 2022 | respiratory tract infectious disorder | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Withdrawn | No outcome recorded |
| — | NCT01414010 Comparator | Aug 2011 → Feb 2012 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT03165253 Background | Jun 2011 → Jun 2012 | Helicobacter pylori infectious disease | Bulent Ecevit University | Completed | No outcome recorded |
| — | NCT04352062 Background | Jan 2011 → Oct 2018 | — | Medical University of Lodz | Completed | No outcome recorded |
| — | NCT01166945 Comparator | Nov 2010 → Feb 2016 | sinusitis | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT01253980 Comparator | Jul 2010 → Sep 2011 | toxic pneumonitis | University of Cape Town | Completed | No outcome recorded |
| — | NCT01909999 Background | Mar 2010 → Oct 2012 | incisors, lower central, absence of | Renato Correa Viana Casarin | Completed | No outcome recorded |
| — | NCT01168063 Background | Feb 2010 → Mar 2012 | Helicobacter pylori infectious disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00844337 Comparator | Mar 2009 → Sep 2013 | infectious disease with sepsis | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT01745328 Comparator | Jan 2009 → Mar 2013 | urinary tract infection | Beijing Institute of Disease Control and Prevention | Unknown | No outcome recorded |
| — | NCT01306786 Comparator | Nov 2008 → Oct 2010 | Helicobacter pylori infectious disease | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00983034 Comparator | Mar 2006 → Dec 2008 | membranous glomerulonephritis, nephrotic syndrome | Istanbul University | Completed | No outcome recorded |
| — | NCT00335309 Comparator | Oct 2005 → Aug 2013 | chronic rhinosinusitis | Ohad Ronen | Completed | No outcome recorded |
| — | NCT01012843 Comparator | Sep 2005 → Jan 2008 | anal fistula | Ankara University | Completed | No outcome recorded |
| — | NCT00662987 Comparator | Sep 2005 → May 2007 | tonsillitis | Weill Medical College of Cornell University | Completed | No outcome recorded |
| — | NCT00135603 Comparator | Feb 2004 → Feb 2008 | appendicitis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01156740 Comparator | Aug 2001 → Apr 2003 | pharyngitis, streptococcal infection | Johns Hopkins University | Completed | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2005-02-10 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Amoxicillin And Clavulanate Potassium Chewable Tablets tevapharm.com ↗ |
| 2004-05-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Amoxicillin And Clavulanate Potassium For Oral Suspension, 200 mg and 400 mg tevapharm.com ↗ |
| 2004-03-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Amoxicillin/Clavulanate Potassium For Oral Suspension tevapharm.com ↗ |
| 2003-11-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Court of Appeals Affirms Teva's Augmentin® Patent Challenge tevapharm.com ↗ |
| 2002-12-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Amoxicillin for Oral Suspension tevapharm.com ↗ |
| 2002-10-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Updated Outlook on 4th Quarter 2002 Earnings in Light of Amox/Clav ANDA Approval tevapharm.com ↗ |
| 2002-10-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Generic Version of Augmentin® tevapharm.com ↗ |
| 2002-10-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of 500mg/125mg Strength of Generic Version of Augmentin® tevapharm.com ↗ |
| 2002-05-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Federal Judge Invalidates Remaining Augmentin Patents tevapharm.com ↗ |
| 2002-03-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Federal Judge Invalidates Augmentin Patents tevapharm.com ↗ |
| 2000-09-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives First Generic Approval for Amoxicillin 500 and 875 mg Tablets tevapharm.com ↗ |
Evidence & citations 60 cited values
Every value below carries the sentence it was read from. 844 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amoxicillin | “Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg...” PMID 16961802 ↗ Oct 2006684“Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to...” NCT01730352 ↗ “14-day bismuth quadruple therapy (pantoprazole, bismuth subcitrate, tetracycline, and metronidazole for 14 days) or 14-day hybrid therapy (a 7-day dual therapy with...” PMID 28807915 ↗ Oct 2017 “A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e.,...” NCT06687473 ↗ “Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or...” PMID 39434634 ↗ Sep 2024 “patients in the control group will receive a prescription for amoxicillin 500 milligrams (mg) (three times daily for 7 days), while patients in the intervention group will...” NCT05266040 ↗ “with initiation of antibiotic therapy at day 1 with Amoxicillin/clavulanic acid IntraVeinous (IV) in 2 doses daily for a minimum of 24 hours and a maximum of 48 hours with a...” NCT07587450 ↗ “A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole...” NCT01967758 ↗ “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid...” NCT01388413 ↗ “a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by...” NCT02547038 ↗ “Group 1: (110) participants received reverse hybrid regimen in the form of clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500 mg tid for...” NCT04039412 ↗ “Treatment for H. pylori Patients with positive Urea Breath Test (positive for H. pylori infection) will be started on eradication therapy of H. pylori (oral esomeprazole 40mg...” NCT02112812 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 “In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly...” NCT01761214 ↗ “sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe...” NCT01418300 ↗ “12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day),...” NCT06973889 ↗ “Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine...” NCT02922075 ↗ “a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and...” NCT03779074 ↗ “An Open-label, Fixed-sequence Study to Evaluate the Drug-drug Interactions Between Tegoprazan Tablets and Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and...” NCT05915871 ↗ “patients will receive concomitant therapy comprising of pantoprazole (40 mg twice daily), amoxicillin (1 gm twice a day), clarithromycin (500 mg twice a day) and metronidazole...” NCT06050824 ↗ “A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all...” NCT07146594 ↗ “Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with...” NCT03362697 ↗ “Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole...” NCT00885417 ↗ “Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid,...” NCT03565484 ↗ “(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days :...” NCT02108184 ↗ “The intervention group will be treated with Esomeprazole 40 mg every 8 hours, Amoxicillin 1 gr every 8 hours, Metronidazole 500 mg every 8 hours, Bismuth subsalicylate 369 mg...” NCT05664685 ↗ “Patients with bacteriologically proven H pylori infection will be randomly allocated to either empirical usual treatment with PPI , amoxicillin 1g, clarithromycin 500 mg X 2...” NCT01168063 ↗ “Eradication group patients received oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week, whereas control group patients received no H...” PMID 29800546 ↗ May 2018 “The adjunctive agents evaluated in this study will be a combination of systemic antibiotics (amoxicillin and metronidazole) and the probiotic Bifidobacterium animalis subsp....” NCT07592416 ↗ “esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks” NCT01547559 ↗ “When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.” NCT04211649 ↗ “Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)).” NCT05444439 ↗ “A combination of Dexlansoprazole (60mg twice daily) with Levofloxacin (500mg once daily) and Amoxicillin (1g twice daily) for the eradication of Helicobacter pylori infection.” NCT07344506 ↗ “Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days” NCT00643539 ↗ “Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID” NCT04209933 ↗ “pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg, amoxicillin 1 g for another 5 days” NCT02359435 ↗ “One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage” NCT01561703 ↗ “Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.” NCT02894268 ↗ “The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:” NCT01980095 ↗ “Eligible patients were randomised to receive LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day) and lansoprazole (30 mg twice a day) for 7 days” PMID 20427390 ↗ May 2010 “The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.” NCT03968302 ↗ “A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), bismuth subcitrate (or bismuth subsalicylate), amoxicillin, and metronidazole.” NCT07260006 ↗ “esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days” NCT01085786 ↗ “Keverprazan dual therapy for 10 days (K10 group): Keverprazan 20 mg per dose, twice daily (bid) + Amoxicillin 1 g per dose, three times (tid) daily, for 10 days.” NCT07122024 ↗ “Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first l” NCT03802318 ↗ “rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid” NCT01566643 ↗ “triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)” NCT03654781 ↗ “RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin” NCT03198507 ↗ “Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days” NCT05614934 ↗ “rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.” NCT01573975 ↗ “In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.” NCT02761005 ↗ “Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid” NCT02835560 ↗ “or (L-group) which received (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice per day for two weeks).” PMID 34218802 ↗ Jul 2021 “lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days” NCT01537055 ↗ “2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days” NCT05749081 ↗ “amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week” NCT06065267 ↗ “After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012).” NCT04051255 ↗ “Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).” NCT04110587 ↗ “Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.” NCT04600752 ↗ “Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days” NCT06318104 ↗ “Amoxicillin/clavulanic acid (isolates sensitive to ampicillin) 1 g/8h iv - Piperacillin/tazobactam (isolates sensitive to ampicillin) 4 g/8h (i.v.)” NCT05394298 ↗ “Patients sensitive to clarithromycin are assigned to the Clarithromycin Group (receiving a regimen of vonoprazan, amoxicillin, and clarithromycin)” NCT07533422 ↗ “standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin/clavulanic acid,” PMID 40119275 ↗ Mar 2025 “Group 1 will receive clarithromycin 500 mg twice daily (bid), amoxicillin 1 g bid, and lansoprazole 30 mg bid (Pylopac®, Medix SA de CV, Mexico);” NCT02726269 ↗ “pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days” NCT01769365 ↗ “with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily” NCT02646332 ↗ “H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.” NCT02776371 ↗ “will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days” NCT02547025 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01712711 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01759628 ↗ “vonoprazan 20 mg twice daily (30 minutes before meal), Amoxicillin 1 g twice daily (After meal), Levofloxacin 500 mg once daily for 14 days” NCT07537634 ↗ “priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.” NCT02689583 ↗ “Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days” NCT02395458 ↗ “Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days” NCT01520181 ↗ “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid.” NCT03592069 ↗ “esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days.” NCT06823791 ↗ “Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.” NCT02934152 ↗ “vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days” NCT07142798 ↗ “Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg QID for 14 days.” NCT07104318 ↗ “pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily” NCT04566211 ↗ “Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)” NCT03060473 ↗ “Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week” NCT04707092 ↗ “PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.” NCT05455372 ↗ “Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.” NCT02054676 ↗ “PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID” NCT01568944 ↗ “Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.” NCT05133193 ↗ “10 days standard triple therapy (Omeprazole 0.8-1.0mg/kg.d,bid, Amoxicillin 30-50mg/kg.d bid， Clarithromycin 15-20mg/kg.d bid)” NCT02635191 ↗ “1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).” NCT03050359 ↗ “1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).” NCT03050307 ↗ “D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi” NCT01042184 ↗ “clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days” NCT05332444 ↗ “Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days.” NCT01628367 ↗ “esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days” NCT05549115 ↗ “These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid.” NCT02605122 ↗ “10-day HD-PPI-TT (60 mg lansoprazole/500 mg clarithromycin/1 g amoxicillin, each administered twice daily for 10 days)” PMID 29804294 ↗ Jun 2018 “Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days” NCT02557932 ↗ “10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d” NCT01572597 ↗ “esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.” NCT03779087 ↗ “Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.” NCT01745328 ↗ “Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days” NCT05449028 ↗ “Standard triple therapy will be based on Esomeprazole 20 mg BD, Clarithromycin 500mg BD and Amoxicillin 1gm BD.” NCT07010744 ↗ “H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.” NCT02933229 ↗ “Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks” NCT00716183 ↗ “dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days” NCT02541786 ↗ “Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days” NCT05184491 ↗ “Subjects who have negative puncture and intradermal test results will be given the oral amoxicillin challenge” NCT01818336 ↗ “They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).” NCT01805934 ↗ “Regimen 2(R2): Levofloxacin 500mg OD plus Amoxicillin 1gm BD for 14 days and omeprazole 40mg Bd for 6 weeks.” NCT07021729 ↗ “3) amoxicillin or amoxicillin/clavulanic acid provided that the isolated E. coli is determined susceptible” NCT07236944 ↗ “Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days.” NCT03508921 ↗ “1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days” NCT05649709 ↗ “Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days” NCT01002443 ↗ “Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.” NCT04209777 ↗ “Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.” NCT06080698 ↗ “Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)” NCT01654549 ↗ “Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.” NCT04438655 ↗ “ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).” NCT02803216 ↗ “All participants will be given a 5-day (Day 1-5) course of Amoxicillin + Clavulanate 875/125 mg × 2.” NCT06250413 ↗ “Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks” NCT05297695 ↗ “antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days” NCT03043066 ↗ “Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose” NCT04620746 ↗ “Vonoprazan 20mg twice daily+Amoxicillin 1g three times daily+Bismuth 220mg twice daily for 7 days” NCT07232095 ↗ “Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.” NCT01678027 ↗ “rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.” NCT04061447 ↗ “A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin” NCT07308041 ↗ “Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID” NCT06591494 ↗ “Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.” NCT01133951 ↗ “Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)” NCT01967329 ↗ “treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole)” NCT03177629 ↗ “Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid” NCT05432115 ↗ “Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid” NCT05802888 ↗ “Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery” NCT04856319 ↗ “Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid” NCT04626193 ↗ “vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days” NCT05371249 ↗ “Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin” NCT03376984 ↗ “Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)” NCT01061437 ↗ “esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days” NCT04006340 ↗ “Children in this arm will receive a 7 day course of amoxicillin (standard of care)” NCT03568643 ↗ “rabeprazole (40 mg daily) plus amoxicillin (1 g twice daily) for the first 5 days” PMID 12641522 ↗ Mar 2003 “Omeprazole 40 mg BID, Amoxicillin 1 g BID, Clarithromycin 500 mg BID for 14 days.” NCT07312721 ↗ “esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.” NCT02978157 ↗ “Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily” NCT01356641 ↗ “Amoxicillin is taken at evenly spaced intervals (approximately every 8 hours).” NCT07624422 ↗ “amoxicillin was used before and after implant surgery for prophylactic reasons” NCT02867982 ↗ “Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day” NCT04660123 ↗ “Amoxicillin and clavulanic acid in fixed dose combination will be administered” NCT05340257 ↗ “with amoxicillin 1,000 mg plus clarithromycin 500 mg twice daily for 10 days” PMID 40462641 ↗ Jun 2025 “First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.” NCT04803422 ↗ “2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night)” NCT06055257 ↗ “17 of 88 patients (19.3%) who received amoxicillin combined with sulbactam” PMID 26251066 ↗ Aug 2015 “Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice” NCT01938534 ↗ “esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d.” NCT01306786 ↗ “Amoxicillin (Kymoxin®, Yuhan Co. Ltd., Seoul, Korea) 1 g, bid, for 7 days” NCT02090738 ↗ “Individuals received either azithromycin or amoxicillin for 3 or 7 days” NCT05169255 ↗ “amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily” NCT02368470 ↗ “rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily” NCT03108287 ↗ “Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid” NCT05586113 ↗ “Amoxicillin - antibiotic used in combination for enhanced efficacy” NCT07150286 ↗ “* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS” NCT01559753 ↗ “D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days” NCT03156855 ↗ “Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days” NCT05933031 ↗ “Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo” NCT00713947 ↗ “Amoxicillin 500 mg, Metronidazole 500 mg, Diclofenac sodium 50 mg” NCT07304882 ↗ “combined with systemic metronidazole (MTZ) and amoxicillin (AMX).” PMID 27013640 ↗ Mar 2016 “Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid” NCT05438550 ↗ “D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days” NCT03148366 ↗ “Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days)” NCT01909999 ↗ “This includes: Nitrofurantoin, Cephalexin, and Amoxicillin.” NCT03275623 ↗ “lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm” NCT01906879 ↗ “oral antibiotic regimen (e.g. amoxicillin + metronidazole)” NCT04140903 ↗ “* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg” NCT01734759 ↗ “rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days” NCT01163435 ↗ “500 mg amoxicillin combined with 125 mg clavulanic acid” NCT03435900 ↗ “Amoxicillin 500 mg (2 tablets twice daily for 14 days)” NCT07224035 ↗ “Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days” NCT01725906 ↗ “Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid” NCT05840588 ↗ “rabeprazole 20mg qid,amoxicillin 750mg qid for 14days” NCT01265069 ↗ “2g Amoxicillin given 1 hour prior to instrumentation” NCT07077122 ↗ “D1-D7: (esomeprazole + amoxicillin bid) for 7 days” NCT03722433 ↗ “Days 3-7: Oral Amoxicillin 500 mg every 8 hours” NCT06917157 ↗ “bismuth, vonoprazan and amoxicillin for 14 days” NCT07576959 ↗ “treatment with PPI, metonidazole, amoxicillin” NCT03431688 ↗ “amoxicillin ( Tablets 25mg/tablet,100mg bid)” NCT05586464 ↗ “Amoxicillin ('Amoksicilin') 1 g bid 14 days.” NCT03572777 ↗ “amoxicillin 1000mg twice daily for 14 days” NCT04713670 ↗ “amoxicillin (1 g, bid) from day 1 to day 5” NCT00656968 ↗ “•Doxycyclin, amoxicillin and metronidazole” NCT02345733 ↗ “Doxycyclin, amoxicillin and metronidazole” NCT02217722 ↗ “amoxicillin orally, 500 mg, tid, 14 days” NCT02147249 ↗ “A is amoxicillin (1000 mg thrice daily)” NCT06687499 ↗ “amoxicillin 1g twice daily for 14 days” NCT03321773 ↗ “Amoxicillin 1000 mg orally twice daily” NCT01723059 ↗ “Omeprazole+Amoxicillin+Clarithromycin” NCT03365609 ↗ “Amoxicillin 1000 mg 2x1, for 14 days” NCT03997279 ↗ “amoxicillin® 1 g bid 5 days (D1-D5)” NCT02373280 ↗ “Amoxicillin 500mg 2 cap twice daily” NCT05786807 ↗ “amoxicillin 1g bid for first 5 days” NCT01760824 ↗ “Amoxicillin 1000 mg bid for 10 days” NCT02047994 ↗ “Amoxicillin (Amoxil®) 500 g b.i.d.” NCT02045251 ↗ “amoxicillin granules (A Mo Xian)” NCT04034641 ↗ “amoxicillin 1g three times daily” NCT05635942 ↗ “Amoxicillin (250mg once daily)” NCT07202949 ↗ “amoxicillin (1 g x 2 per day)” NCT04769583 ↗ “Amoxicillin capsules 1000mg” NCT07606833 ↗ “Amoxicillin 1000 mg Tablets” NCT03021590 ↗ “3×500 mg oral amoxicillin” NCT07148622 ↗ “Amoxicillin (Hiconcil)” NCT05655338 ↗ “Ampicillin/Amoxicillin” NCT05206500 ↗ “Amoxicillin 1g bid PO” NCT04512638 ↗ “Amoxicillin 1000 mg” NCT07068607 ↗ “Amoxicillin 1 g bd” NCT02092506 ↗ “amoxicillin 500 mg” NCT02547012 ↗ “Amoxicillin” NCT01561703 ↗ “Amoxicillin” NCT06207786 ↗ “amoxicillin” NCT03704506 ↗ “Amoxicillin” NCT02099240 ↗ |
| Known as | A Mo Xian | “amoxicillin granules (A Mo Xian)” NCT04034641 ↗ |
| Known as | A/C | “Amoxicillin-clavulanate (A/C) is currently the most effective oral antimicrobial in treating children with acute otitis media (AOM), but the standard dosage of 90 mg...” PMID 28438923 ↗ Jun 2017 |
| Known as | AMO | “In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children” NCT04721704 ↗ |
| Known as | Amoksicilin | “Amoxicillin ('Amoksicilin') 1 g bid 14 days.” NCT03572777 ↗ |
| Known as | Amoksicillintrihydrat | “Amoxicillin (Amoksicillintrihydrat)” NCT02323412 ↗ |
| Known as | Amolin | “D1-7: Nexium (40 mg, bid), Amolin (1 gm, bid)” NCT01032655 ↗ |
| Known as | AMOX | “Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.” NCT00066066 ↗ |
| Known as | amox/clav | “In the first trial, we compared the efficacy of amoxicillin/clavulanate (amox/clav) administered for 10 days vs. that of placebo” PMID 37171965 ↗ Apr 2023 |
| Known as | Amoxicillin (generic drug) | “Amoxicillin (generic drug)” NCT02783404 ↗ |
| Known as | Amoxicillin (Hiconcil) | “Amoxicillin (Hiconcil)” NCT05655338 ↗ |
| Known as | amoxicillin / clav. acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00818610 ↗ |
| Known as | Amoxicillin Clavulinate | “Augmentin is the trade name and the generic is Amoxicillin Clavulinate or clavulinic acid.” NCT04198129 ↗ |
| Known as | Amoxicillin Trihydrate | “co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor” NCT01870167 ↗1“Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days” NCT01725906 ↗ |
| Known as | amoxicillin-clavulanate | “Amoxicillin-clavulanate (A/C) is currently the most effective oral antimicrobial in treating children with acute otitis media (AOM), but the standard dosage of 90 mg...” PMID 28438923 ↗ Jun 201738“Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after...” NCT02365623 ↗ “Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.” NCT00368537 ↗ “Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.” NCT06443502 ↗ “PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h” NCT01669980 ↗ “Amoxicillin-clavulanate 875mg tid PO” NCT04512638 ↗ |
| Known as | amoxicillin-clavulanate potassium | “Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.” NCT00377260 ↗3“treated with amoxicillin clavulanate potassium (625mg bid)” NCT02315547 ↗ |
| Known as | Amoxicillin-clavulanic | “Augmentin (Amoxicillin-clavulanic)” NCT00520949 ↗ |
| Known as | Amoxicillin-clavulanic Acid | “These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid.” NCT02605122 ↗17“comparing amoxicillin-clavulanic acid administered for 7 days to a placebo.” NCT00190437 ↗ “amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment” NCT06929702 ↗ “seven day course of oral Amoxicillin-Clavulanic acid” NCT01715610 ↗ “Amoxicillin-Clavulanic Acid” NCT02099240 ↗ |
| Known as | Amoxicillin-Potassium Clavulanate Combination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02258763 ↗ |
| Known as | Amoxicillin/CA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532409 ↗ |
| Known as | Amoxicillin/clavulunate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01370616 ↗ |
| Known as | Amoxicillin/clavulunate potassium | “participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28” NCT01370616 ↗ |
| Known as | Amoxicillin: Amoxil | “Amoxicillin: Amoxil” NCT01219764 ↗ |
| Known as | Amoxicilline | “omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1” NCT03757650 ↗ |
| Known as | Amoxicilline Sandoz | “Drug: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days” NCT04669717 ↗ |
| Known as | Amoxicyllin | “Clarithro -pantoprazole- Metronidazole - Amoxicyllin” NCT06050824 ↗ |
| Known as | Amoxil | “Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days.” NCT01568944 ↗ |
| Known as | Amoxycillin | “Qingre Huashi Granules 1 package twice daily, Rabeprazole 20mg triple daily, Amoxycillin 1g triple daily.” NCT05364619 ↗14“PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks” NCT02033408 ↗ “Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD” NCT02108704 ↗ “Omeprazole, amoxycillin, clarithromycin” NCT03491995 ↗ “amoxycillin 1 gm twice daily” NCT06101420 ↗ |
| Known as | Amoxycillin or Ibiamox | “Amoxycillin or Ibiamox” NCT00467571 ↗ |
| Known as | AMPC | “Most patients who have failed in the eradication of H. pylori infection by triple therapy with a PPI, amoxicillin (AMPC) and clarithromycin (CAM) at standard doses have...” NCT00197418 ↗ |
| Known as | AMX | “The primary objective of this study is to demonstrate the non-inferiority, at the assessment visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI)...” NCT00393744 ↗4“The benefits of amoxicillin (AMX) plus metronidazole (MTZ) adjunctive to scaling and root planing (SRP) require further investigation, particularly in individuals with a high...” NCT05934227 ↗ “MTZ + amoxicillin (AMX) in the treatment of generalized chronic periodontitis (ChP).” PMID 23016867 ↗ Sep 2012 “amoxicillin + metronidazole (AMX + MET) versus clarithromycin (CLM)” PMID 31257591 ↗ Jul 2019 “combined with systemic metronidazole (MTZ) and amoxicillin (AMX).” PMID 27013640 ↗ Mar 2016 |
| Known as | Antibiotics, Amoxicillin ,Amoxicillin | “Antibiotics, Amoxicillin ,Amoxicillin®” NCT03897244 ↗ |
| Known as | Augmentin | “Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with...” NCT00299455 ↗16“For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours” NCT03935828 ↗ “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “Augmentin” NCT04751500 ↗ |
| Known as | Augmentin ES-600 | “Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.” NCT00377260 ↗ |
| Known as | benzylpenicilloate | “benzylpenicilloate” NCT01818336 ↗ |
| Known as | benzylpenilloate | “benzylpenilloate” NCT01818336 ↗ |
| Known as | Cefamandol | “Cefamandol” NCT02099240 ↗ |
| Known as | Ceftmetazole | “Ceftmetazole” NCT02099240 ↗ |
| Known as | Clamoxyl | “Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days” NCT00643539 ↗ |
| Known as | Co-Amoxiclav | “63 were given a single intravenous dose of Enhancin [Co-Amoxiclav] at induction while the remaining half received a five days oral course of the same postoperatively.” PMID 21961644 ↗ Sep 201116“All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.” NCT05964140 ↗ “comparing no prophylaxis with prophylaxis (co-trimoxazole 15 mg/kg per day or co-amoxiclav 15 mg/kg per day) for 12 months.” PMID 18977988 ↗ Nov 2008 “Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily.” NCT02916134 ↗ “Co-amoxiclav, vancomycin” NCT04048304 ↗ “Co-amoxiclav” NCT04751500 ↗ |
| Known as | Colistemetate | “Colistemetate” NCT02099240 ↗ |
| Known as | Doxycicline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101420 ↗ |
| Known as | Drug A | “Drug A is an antifungal agent.” NCT03897257 ↗ |
| Known as | Enhancin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01267942 ↗ |
| Known as | Esomeprazol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315676 ↗ |
| Known as | Hiconcil | “Clarithromycin(Klaricid), Amoxicillin(Hiconcil) and” NCT01575899 ↗ |
| Known as | Iramox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711176 ↗ |
| Known as | Para-aminosalicyclic acid | “Para-aminosalicyclic acid” NCT02099240 ↗ |
| Known as | PIP-TAZ | “4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch)” PMID 30861061 ↗ Nov 2019 |
| Known as | Piperacillin-tazobactam | “Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗35“The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem,...” NCT04879030 ↗ “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “various combination of antibiotics (ampicillin, metronidazole, clindamycin, piperacillin-tazobactam, gentamicin)” NCT01994993 ↗ “The antibiotics used in the study are benzylpenicillin, cloxacillin, piperacillin-tazobactam and vancomycin.” NCT07575009 ↗ “Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin” NCT03409679 ↗ “meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin” NCT05977868 ↗ “Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.” NCT06080698 ↗ “piperacillin-tazobactam, an extended-spectrum penicillin with beta-lactamase inhibitor” NCT05094154 ↗ “amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment” NCT06929702 ↗ “Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g” NCT01667094 ↗ “Either meropenem or piperacillin-tazobactam” NCT03582007 ↗ |
| Known as | pipercillin/tazobactam | “Tazocin (pipercillin/tazobactam)” NCT07096310 ↗ |
| Known as | Synercid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00240747 ↗ |
| Known as | Tazocin | “14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin” NCT02894684 ↗ |
| Known as | ticarcillin-clavulanate | “Ticarcillin-clavulanate is a sterile injectable antibacterial combination consisting of the semisynthetic antibiotic ticarcillin disodium, and the β-lactamase inhibitor...” NCT01229046 ↗ |
| Known as | Ticarcillin-clavulanic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01229046 ↗ |
| Known as | Timentin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02158442 ↗ |
| Known as | zosyn | “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ |
| Action | Inhibit | “possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes” NCT01229046 ↗ |
| Modality | Other / unclassified | “Beta-lactam antibiotic” NCT00716183 ↗ |
| Route | Oral | “orally administered antibiotics metronidazole and amoxicillin” NCT00066066 ↗ |